Is AstraZeneca plc A Buy After This Week’s Results?

Contrarian buy or value trap? Roland Head looks at the latest numbers from AstraZeneca plc (LON:AZN) and asks whether long-term growth forecasts are realistic.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in pharmaceutical heavyweight AstraZeneca (LSE: AZN) fell by more than 4% on Thursday morning after the firm published its full-year results.

Core earnings of $4.26 per share exactly matched the latest forecasts, and the full-year dividend of $2.80 is also in line with expectations. However, although the stock’s 4.5% dividend yield is attractive, AstraZeneca’s results didn’t provide the same level of reassurance about the future as those from GlaxoSmithKline on Wednesday.

What’s the problem?

AstraZeneca’s sales fell by 7% to $24,708m in 2015, while the firm’s core (adjusted) operating profit fell by 1% to $6,902m. In today’s results, the firm warned investors to expect a further “low to mid-single digit percentage decline” in both revenue and core earnings per share in 2016.

AstraZeneca still seems to be suffering badly from falling sales and profit margins on products that have lost patent protection. Some of the company’s biggest earners were hit hard last year. Sales of Crestor, a statin, fell by 3% to $5,107m after it lost market exclusivity in the US in May. Sales of Symbicort fell by 3% to $3,394m while revenue from Nexium fell by a whopping 26% to $2,496m.

As these three products accounted for 45% of AstraZeneca’s revenue in 2015, it’s easy to see why further declines are expected this year. Although many of the firm’s newer products are delivering strong sales growth, they mostly have much lower levels of sales. This means it will take some time to regain the revenue lost by older products.

Is any of this a surprise?

It’s probably true to say that most of this bad news was already reflected in the price of AstraZeneca’s shares. It’s also true that turning around a business like this will always take a number of years.

However, investors will remember that US giant Pfizer offered £55 per share for AstraZeneca two years ago. The shares would have to rise by 30% from today’s share price of £42 to match that figure.

Pascal Soriot, AstraZeneca’s chief executive, convinced investors not to back the Pfizer deal by promising long-term sustainable growth. Back in May 2014, Mr Soriot said he was targeting annual revenues of more than $45bn by 2023, with sustained revenue growth from 2017 to 2023.

Given that last year’s revenues totalled just $24bn, 2016 must be the last year of declines if AstraZeneca is to hit these forecasts. I think that today’s share price wobble reflects the risk involved in trusting long-term forecasts that were produced to defend the firm during a takeover battle.

Is the stock a contrarian buy?

There’s no doubt that AstraZeneca does have a pipeline of promising new products that should deliver long-term sales growth. The exact numbers may not match up with 2014’s statement, but the direction of movement is likely to be upwards.

On this basis, the stock doesn’t look expensive in my view, as long as you’re investing on a three-to-five-year timescale. The shares trade on around 15 times forecast earnings for 2016, and the 4.5% yield provides an attractive reward for your patience.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »